Top 10 Best-Selling Cancer Drugs, Q1–Q3 2017
15% Year-Over-Year Growth, with Sales Set to More than Double by 2022
Epigenetic Drugs: Team Players in Combo Therapies
Scientists May Be Better Able to Destroy Tumors and Possibly Reverse CNS Decline
Key Trends in 2018 in the Biopharmaceutical Market
Interview with Nigel Darby, Advisor, GE Healthcare Life Sciences
Seeking New Users for iSeq
The Changing Sequencing Landscape
For full access to this article login to GEN Select now.
Methods for Maximizing Antibody Yields
New Technologies Could Help Usher in Lower Costs and Increased Availability
- Among recombinant proteins, antibodies stand out as the strongest candidates for new therapeutic drugs and represent the majority of submissions to the FDA and other regulatory agencies. Total sales of recombinant antibodies reached $15.8 billion in 2006 and are projected to go to $28.6 billion by 2010, according to ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.